The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification.
J. Leonard
Consultant or Advisory Role - Millennium
Honoraria - Millennium
Research Funding - Millennium
J. Reeves
No relevant relationships to disclose
B. Ferhanoglu
No relevant relationships to disclose
K. T. Doner
No relevant relationships to disclose
H. Eom
No relevant relationships to disclose
I. W. Flinn
Research Funding - Millennium
J. Raposo
Consultant or Advisory Role - Roche
N. M. Chowhan
Consultant or Advisory Role - Millennium
C. Suh
No relevant relationships to disclose
S. Noga
Consultant or Advisory Role - Millennium
Honoraria - Millennium
Research Funding - Millennium
G. Tumyan
No relevant relationships to disclose
S. Aung
No relevant relationships to disclose
J. Hajdenberg
No relevant relationships to disclose
B. K. Ulrich
No relevant relationships to disclose
K. B. Pendergrass
No relevant relationships to disclose
G. Mulligan
Employment or Leadership Position - Millennium
A. Rizo
Employment or Leadership Position - Janssen Oncology
S. Kussick
Employment or Leadership Position - PhenoPath Laboratories
F. Offner
No relevant relationships to disclose